RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-07-27 | 2023-07-25+ | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +40.0K | 164.0K | +32% | +$88.8K |
| DM | 2023-07-27 | 2023-07-25+ | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $14.36 | -40.0K | 144.0K | -22% | -$574.2K |
| D | 2023-07-21 | 2023-07-20 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 915.8K | -1% | $0 |
| D | 2023-07-21 | 2023-07-20 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 925.8K | +1% | $0 |
| DM | 2023-07-19 | 2023-07-17+ | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $12.73 | -60.0K | 144.0K | -29% | -$763.8K |
| DM | 2023-07-19 | 2023-07-17+ | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +60.0K | 174.0K | +53% | +$133.2K |
| DM | 2023-07-19 | 2023-07-18+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 855.4K | +10% | +$166.5K |
| DM | 2023-07-19 | 2023-07-18+ | RXRX | Secora Michael | CFO | S - Sale+OE | $14.58 | -50.0K | 830.9K | -6% | -$729.0K |
| M | 2023-07-14 | 2023-07-12+ | RXRX | Burrell Terry-Ann | Dir | S - Sale | $12.07 | -117.0K | 69.5K | -63% | -$1.41M |
| D | 2023-07-14 | 2023-07-12 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 947.6K | +3% | +$77.5K |
| DM | 2023-07-14 | 2023-07-12 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $13.14 | -31.8K | 915.8K | -3% | -$418.0K |
| DMI | 2023-07-14 | 2023-07-12 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| DMI | 2023-07-14 | 2023-07-12 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $11.77 | -25.0K | 0 | -100% | -$294.2K |
| 2023-07-13 | 2023-07-11 | RXRX | Borgeson Blake | Dir | S - Sale | $6.89 | -8,885 | 7.52M | -0.1% | -$61.2K | |
| 2023-07-06 | 2023-07-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,609 | 637.5K | +0.3% | $0 | |
| 2023-07-06 | 2023-07-03 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,863 | 72.0K | +3% | $0 | |
| 2023-07-06 | 2023-07-03 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +1,440 | 9,378 | +18% | $0 | |
| 2023-07-06 | 2023-07-03 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,541 | 53.6K | +5% | $0 | |
| D | 2023-07-03 | 2023-06-29 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $7.49 | -3,000 | 424.2K | -0.7% | -$22.5K |
| D | 2023-07-03 | 2023-06-29 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 427.2K | +0.7% | +$3,180 |
| 2023-06-29 | 2023-06-27 | RXRX | Borgeson Blake | Dir | S - Sale | $7.39 | -8,885 | 7.53M | -0.1% | -$65.7K | |
| D | 2023-06-21 | 2023-06-16 | RXRX | Burrell Terry-Ann | Dir | A - Grant | $0.00 | +12.6K | 171.8K | +8% | $0 |
| D | 2023-06-21 | 2023-06-16 | RXRX | HERSHBERG ROBERT | Dir | A - Grant | $0.00 | +12.6K | 38.6K | +48% | $0 |
| D | 2023-06-21 | 2023-06-16 | RXRX | Borgeson Blake | Dir | A - Grant | $0.00 | +12.6K | 7.54M | +0.2% | $0 |
| D | 2023-06-21 | 2023-06-16 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +12.6K | 636.0K | +2% | $0 |
| D | 2023-06-21 | 2023-06-16 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +12.6K | 70.2K | +22% | $0 |
| D | 2023-06-21 | 2023-06-16 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +12.6K | 51.0K | +33% | $0 |
| DM | 2023-06-20 | 2023-06-15+ | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +60.0K | 174.0K | +53% | +$133.2K |
| DM | 2023-06-20 | 2023-06-15+ | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $9.54 | -60.0K | 144.0K | -29% | -$572.4K |
| D | 2023-06-16 | 2023-06-15 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 916.4K | -1% | $0 |
| D | 2023-06-16 | 2023-06-15 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 926.4K | +1% | $0 |
| DM | 2023-06-15 | 2023-06-13+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 842.9K | +10% | +$166.5K |
| DM | 2023-06-15 | 2023-06-13+ | RXRX | Secora Michael | CFO | S - Sale+OE | $10.00 | -50.0K | 817.9K | -6% | -$500.0K |
| 2023-06-15 | 2023-06-13 | RXRX | Borgeson Blake | Dir | S - Sale | $9.98 | -15.5K | 7.53M | -0.2% | -$154.5K | |
| D | 2023-06-09 | 2023-06-07 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 972.8K | +3% | +$77.5K |
| D | 2023-06-09 | 2023-06-07 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.05 | -56.4K | 916.4K | -6% | -$510.7K |
| D | 2023-06-07 | 2023-06-01 | RXRX | Mauro David J | Chief Medical Off | A - Grant | $0.00 | +190.7K | 190.7K | New | $0 |
| M | 2023-06-05 | 2023-06-01+ | RXRX | Virani Shafique | Chief Business Off | S - Sale | $8.73 | -42.9K | 161.8K | -21% | -$374.0K |
| D | 2023-06-02 | 2023-05-31 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $8.63 | -3,000 | 424.2K | -0.7% | -$25.9K |
| D | 2023-06-02 | 2023-05-31 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 427.2K | +0.7% | +$3,180 |
| 2023-06-01 | 2023-05-30 | RXRX | Borgeson Blake | Dir | S - Sale | $8.79 | -8,885 | 7.54M | -0.1% | -$78.1K | |
| 2023-05-17 | 2023-05-16 | RXRX | Borgeson Blake | Dir | S - Sale | $5.09 | -8,885 | 7.55M | -0.1% | -$45.2K | |
| 2023-05-17 | 2023-05-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $5.60 | -5,415 | 422.4K | -1% | -$30.3K | |
| 2023-05-17 | 2023-05-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $5.60 | -11.7K | 941.6K | -1% | -$65.3K | |
| 2023-05-17 | 2023-05-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $5.60 | -2,230 | 185.1K | -1% | -$12.5K | |
| 2023-05-17 | 2023-05-15 | RXRX | Secora Michael | CFO | F - Tax | $5.60 | -4,760 | 790.2K | -0.6% | -$26.7K | |
| DMI | 2023-05-05 | 2023-05-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $4.90 | -25.0K | 0 | -100% | -$122.6K |
| DM | 2023-05-05 | 2023-01-05+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.3K | 956.4K | +1% | $0 |
| DM | 2023-05-05 | 2023-01-05+ | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -19.0K | 955.0K | -2% | $0 |
| D | 2023-05-05 | 2023-05-03 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 986.3K | +3% | +$77.5K |
| D | 2023-05-05 | 2023-05-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $4.71 | -33.1K | 953.2K | -3% | -$155.8K |
| DMI | 2023-05-05 | 2023-05-03 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| A | 2023-04-28 | 2023-04-03 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,996 | 57.6K | +4% | $0 |
| A | 2023-04-28 | 2022-02-04 | RXRX | Secora Michael | CFO | F - Tax | $11.40 | -678 | 590.4K | -0.1% | -$7,729 |
| MA | 2023-04-28 | 2022-02-04 | RXRX | Secora Michael | CFO | A - Grant | $0.00 | +60.3K | 591.1K | +11% | $0 |
| DMA | 2023-04-28 | 2022-01-05+ | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +75.5K | 601.3K | +14% | $0 |
| DMA | 2023-04-28 | 2022-04-25+ | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -57.0K | 582.8K | -9% | $0 |
| DA | 2023-04-28 | 2022-01-05 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.39 | -18.5K | 582.8K | -3% | -$136.7K |
| 2023-04-20 | 2023-04-18 | RXRX | Borgeson Blake | Dir | S - Sale | $5.93 | -8,885 | 7.56M | -0.1% | -$52.7K | |
| DM | 2023-04-07 | 2023-04-05+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $6.60 | -53.3K | 946.7K | -5% | -$351.7K |
| D | 2023-04-07 | 2023-04-05 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 960.0K | +3% | +$77.5K |
| D | 2023-04-07 | 2023-04-05 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 928.8K | -1% | $0 |
| 2023-04-06 | 2023-04-04 | RXRX | Borgeson Blake | Dir | S - Sale | $6.53 | -8,885 | 7.57M | -0.1% | -$58.0K | |
| 2023-04-05 | 2023-04-03 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,721 | 38.4K | +8% | $0 | |
| 2023-04-05 | 2023-04-03 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,724 | 623.4K | +0.3% | $0 | |
| 2023-04-05 | 2023-04-03 | RXRX | Bogue Zachary | Dir, 10% | A - Grant | $0.00 | +1,542 | 7,938 | +24% | $0 | |
| 2023-04-05 | 2023-04-03 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,996 | 22.6K | +10% | $0 | |
| 2023-03-23 | 2023-03-21 | RXRX | Borgeson Blake | Dir | S - Sale | $7.40 | -8,885 | 7.58M | -0.1% | -$65.7K | |
| D | 2023-03-15 | 2023-03-13 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -3,000 | 938.8K | -0.3% | $0 |
| D | 2023-03-15 | 2023-03-13 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +3,000 | 941.8K | +0.3% | $0 |
| DMI | 2023-03-10 | 2023-03-08 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 20.0K | New | $0 |
| D | 2023-03-10 | 2023-03-08 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 953.8K | -1% | $0 |
| DMI | 2023-03-10 | 2023-03-08 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.10 | -25.0K | 0 | -100% | -$202.5K |
| D | 2023-03-10 | 2023-03-08 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +93.8K | 1.03M | +10% | +$232.5K |
| DM | 2023-03-10 | 2023-03-08+ | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.04 | -85.9K | 963.8K | -8% | -$690.8K |
| 2023-03-09 | 2023-03-07 | RXRX | Borgeson Blake | Dir | S - Sale | $8.33 | -8,885 | 7.59M | -0.1% | -$74.0K | |
| D | 2023-03-06 | 2023-03-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.92 | -18.5K | 940.9K | -2% | -$146.5K |
| DMI | 2023-03-06 | 2023-03-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +2,500 | 1,000 | New | $0 |
| D | 2023-03-06 | 2023-03-02 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +18.5K | 956.4K | +2% | $0 |
| DMI | 2023-03-06 | 2023-03-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale | $7.91 | -2,500 | 0 | -100% | -$19.8K |
| I | 2023-03-03 | 2023-03-02 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.82 | +66.8K | 12.99M | +0.5% | +$522.5K |
| I | 2023-03-02 | 2023-03-01 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.94 | +48.9K | 12.92M | +0.4% | +$388.0K |
| I | 2023-03-01 | 2023-02-28 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.97 | +815 | 12.87M | +0.0% | +$6,496 |
| I | 2023-02-28 | 2023-02-27 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.69 | +52.5K | 12.87M | +0.4% | +$403.7K |
| D | 2023-02-27 | 2023-02-23 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $7.82 | -8,000 | 427.8K | -2% | -$62.6K |
| D | 2023-02-27 | 2023-02-23 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 435.8K | +2% | +$8,480 |
| I | 2023-02-27 | 2023-02-24 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.64 | +109.1K | 12.82M | +0.9% | +$833.7K |
| I | 2023-02-24 | 2023-02-23 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.79 | +51.9K | 12.71M | +0.4% | +$404.0K |
| 2023-02-23 | 2023-02-21 | RXRX | Borgeson Blake | Dir | S - Sale | $7.73 | -8,885 | 7.59M | -0.1% | -$68.7K | |
| I | 2023-02-23 | 2023-02-22 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.83 | +50.9K | 12.66M | +0.4% | +$398.9K |
| I | 2023-02-22 | 2023-02-21 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.74 | +94.4K | 12.61M | +0.8% | +$730.8K |
| I | 2023-02-21 | 2023-02-17 | RXRX | Mubadala Investment Co PJSC | 10% | P - Purchase | $7.71 | +63.4K | 12.51M | +0.5% | +$488.7K |
| 2023-02-17 | 2023-02-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $8.44 | -1,603 | 427.8K | -0.4% | -$13.5K | |
| I | 2023-02-17 | 2023-02-16 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.90 | +42.7K | 12.45M | +0.3% | +$337.2K |
| 2023-02-17 | 2023-02-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $8.44 | -1,346 | 940.9K | -0.1% | -$11.4K | |
| D | 2023-02-17 | 2023-02-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $8.44 | -746 | 189.1K | -0.4% | -$6,296 |
| DM | 2023-02-17 | 2023-02-15+ | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $8.35 | -9,254 | 189.8K | -5% | -$77.2K |
| D | 2023-02-17 | 2023-02-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +7,486 | 197.3K | +4% | +$16.6K |
| 2023-02-17 | 2023-02-15 | RXRX | Secora Michael | CFO | F - Tax | $8.44 | -1,258 | 794.3K | -0.2% | -$10.6K | |
| I | 2023-02-15 | 2023-02-14 | RXRX | Mamoura Diversified Global Holding PJSC | 10% | P - Purchase | $7.95 | +6,300 | 12.40M | +0.1% | +$50.1K |
Purchase Sale Sale after option exercise All abbreviations